Ono Yasumasa, Fujita Yoshihito, Kajiura Takahiro, Okawa Hazuki, Nakashima Juntaro, Isobe Hideo, Fujiwara Yoshihiro
Department of Anesthesiology, Aichi Medical University School of Medicine, 1-1 Yazako Karimata, Nagakute, Aichi, 480-1195, Japan.
JA Clin Rep. 2018 Jul 25;4(1):56. doi: 10.1186/s40981-018-0192-z.
Sugammadex reverses rocuronium by encapsulating it, creating a stable complex that is mainly excreted by the kidneys. Nonetheless, in view of exposure to sugammadex during renal transplantation, current safety data are insufficient. We retrospectively investigated the safety and efficacy of sugammadex in the immediate perioperative period and over long-term follow-up.
We studied 99 consecutive patients who underwent living renal transplantation. We investigated the efficacy of sugammadex and its perioperative complications in the first 48-72 h in the surgical intensive care unit and in the follow-up for 6 months. Before transplantation, 53 patients required hemodialysis. The median serum creatinine concentration was 5.6 mg/dl, and blood urea nitrogen (BUN) was 30 mg/dl. During surgery, the median rocuronium and sugammadex dose was 160 mg (interquartile range 130-185 mg) and 200 mg (200-200 mg), respectively. After transplantation, the median serum creatinine concentration was 2.4 mg/dl at postoperative day 1, and BUN was 21 mg/dl, respectively. No adverse events were recorded during the observation period.
We investigated whether 99 consecutive patients undergoing renal transplantation may benefit from the use of sugammadex. There were no adverse events. We concluded that, in our observational period, sugammadex was efficacious and safe in patients who underwent renal transplantation.
舒更葡糖钠通过包裹罗库溴铵来逆转其作用，形成一种主要经肾脏排泄的稳定复合物。尽管如此，鉴于肾移植期间会接触舒更葡糖钠，目前的安全性数据并不充分。我们回顾性研究了舒更葡糖钠在围手术期即刻及长期随访中的安全性和有效性。
我们研究了99例连续接受活体肾移植的患者。我们调查了舒更葡糖钠在外科重症监护病房最初48 - 72小时及6个月随访期内的有效性及其围手术期并发症。移植前，53例患者需要血液透析。血清肌酐浓度中位数为5.6mg/dl，血尿素氮（BUN）为30mg/dl。手术期间，罗库溴铵和舒更葡糖钠的剂量中位数分别为160mg（四分位间距130 - 185mg）和200mg（200 - 200mg）。移植后，术后第1天血清肌酐浓度中位数为2.4mg/dl，BUN为21mg/dl。观察期内未记录到不良事件。
我们调查了99例连续接受肾移植的患者是否可能从使用舒更葡糖钠中获益。未出现不良事件。我们得出结论，在我们的观察期内，舒更葡糖钠对接受肾移植的患者有效且安全。
